Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo.
Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate.
"We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity."
Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity.
The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.
Persons:
Mohit, Bansal, Takeda, — CNBC's Michael Bloom
Organizations:
Biosciences
Locations:
Wells Fargo